Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annexon, Inc.ANNX · Entity 5011 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annexon, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-06-11 | Direct | 65,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 65,000 · Balance 65,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Global Blood Therapeutics, Inc.
Report date October 05, 2022 · Filed October 06, 2022
Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 1
1 source rowRow 1 · 2022-10-05 · Disposition to issuer · Disposed 226,672 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2022-10-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-10-05 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-05 · Disposition to issuer · Disposed 3,125 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-05 · Disposition to issuer · Disposed 9,060 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-05 · Disposition to issuer · Disposed 13,814 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-05 · Disposition to issuer · Disposed 15,460 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-05 · Disposition to issuer · Disposed 26,454 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-10-05 · Disposition to issuer · Disposed 42,400 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.40 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-10-05 · Disposition to issuer · Disposed 1 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.40 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-10-05 · Disposition to issuer · Disposed 1 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.40 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-10-05 · Disposition to issuer · Disposed 32,098 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.60 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-10-05 · Disposition to issuer · Disposed 35,000 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.44 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-10-05 · Disposition to issuer · Disposed 40,000 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.82 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2022-10-05 · Disposition to issuer · Disposed 36,225 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.48 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2022-10-05 · Disposition to issuer · Disposed 38,739 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.87 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2022-10-05 · Disposition to issuer · Disposed 28,628 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
F2: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.
F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.
F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2018 Filed Feb 16, 2018 19:16 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 692 | $62.30 | $43,111.60 |
DisclosureSEC source: 0000899243-18-004454 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,477 F3 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,000 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 19:16 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-004454 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F2 · balance_after: Includes 676 shares acquired under the Issuer's Employee Stock Purchase Plan ("ESPP") on July 31, 2017 and 435 shares acquired under the ESPP on January 31, 2018, each in a transaction exempt under Rule 16b-3. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:01 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002742 · doc4.xml · derivative · entry 9 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F7 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:01 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $59.60 | $0.00 |
DisclosureSEC source: 0000899243-18-002742 · doc4.xml · derivative · entry 8 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-01-31 F6 · derivative.exercise_date: The shares underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:01 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 4,063 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002742 · doc4.xml · derivative · entry 7 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,375 Underlying: Common Stock · 4,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On January 17, 2017, the Reporting Person was granted 32,500 RSUs, which vest in equal semi-annual installments over 4 years from February 1, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: On January 17, 2017, the Reporting Person was granted 32,500 RSUs, which vest in equal semi-annual installments over 4 years from February 1, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:01 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 1,405 | $59.60 | $83,738.00 |
DisclosureSEC source: 0000899243-18-002742 · doc4.xml · nonDerivative · entry 4 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,058 F3 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,063 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:01 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 4,063 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002742 · doc4.xml · nonDerivative · entry 3 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:01 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002742 · doc4.xml · derivative · entry 6 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 15,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 31, 2018, one of the performance milestones was achieved, resulting in the vesting of 2,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 15,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 31, 2018, one of the performance milestones was achieved, resulting in the vesting of 2,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:01 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 692 | $57.90 | $40,066.80 |
DisclosureSEC source: 0000899243-18-002742 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,400 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,000 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:01 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002742 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:24 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002115 · doc4.xml · derivative · entry 4 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 15,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 24, 2018, one of the performance milestones was achieved, resulting in the vesting of 2,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 15,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 24, 2018, one of the performance milestones was achieved, resulting in the vesting of 2,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:24 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 686 | $58.15 | $39,890.90 |
DisclosureSEC source: 0000899243-18-002115 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,092 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,000 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:24 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002115 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 19:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 601 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-18-001390 · doc4.xml · derivative · entry 12 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,079 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 19:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 601 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-18-001390 · doc4.xml · derivative · entry 11 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,079 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 19:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 198 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-18-001390 · doc4.xml · derivative · entry 10 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,756 Underlying: Common Stock · 198 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on April 6, 2016, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 19:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,600 | $52.85 | $84,560.00 |
DisclosureSEC source: 0000899243-18-001390 · doc4.xml · nonDerivative · entry 7 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,778 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · shares: These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 19:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,400 | $52.85 | $73,990.00 |
DisclosureSEC source: 0000899243-18-001390 · doc4.xml · nonDerivative · entry 6 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,378 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 19:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 601 | $3.40 | $2,043.40 |
DisclosureSEC source: 0000899243-18-001390 · doc4.xml · nonDerivative · entry 5 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 19:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 601 | $3.40 | $2,043.40 |
DisclosureSEC source: 0000899243-18-001390 · doc4.xml · nonDerivative · entry 4 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,177 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 19:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 198 | $3.40 | $673.20 |
DisclosureSEC source: 0000899243-18-001390 · doc4.xml · nonDerivative · entry 3 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 19:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001390 · doc4.xml · derivative · entry 9 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F5 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 15,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 16, 2018, one of the performance milestones was achieved, resulting in the vesting of 2,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 15,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 16, 2018, one of the performance milestones was achieved, resulting in the vesting of 2,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 19:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 877 | $52.10 | $45,691.70 |
DisclosureSEC source: 0000899243-18-001390 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,378 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,000 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 19:59 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-001390 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 17:12 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 601 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-17-029329 · doc4.xml · derivative · entry 9 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,680 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 17:12 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 601 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-17-029329 · doc4.xml · derivative · entry 8 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,680 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 17:12 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 198 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-17-029329 · doc4.xml · derivative · entry 7 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,954 Underlying: Common Stock · 198 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on April 6, 2016, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 17:12 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,400 | $36.55 | $51,170.00 |
DisclosureSEC source: 0000899243-17-029329 · doc4.xml · nonDerivative · entry 5 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,255 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 17:12 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 601 | $3.40 | $2,043.40 |
DisclosureSEC source: 0000899243-17-029329 · doc4.xml · nonDerivative · entry 4 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 17:12 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 601 | $3.40 | $2,043.40 |
DisclosureSEC source: 0000899243-17-029329 · doc4.xml · nonDerivative · entry 3 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 17:12 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 198 | $3.40 | $673.20 |
DisclosureSEC source: 0000899243-17-029329 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 17:12 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,600 | $36.55 | $58,480.00 |
DisclosureSEC source: 0000899243-17-029329 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,255 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · shares: These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 16:30 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 601 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-17-027164 · doc4.xml · derivative · entry 9 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,281 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 16:30 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 601 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-17-027164 · doc4.xml · derivative · entry 8 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,281 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 16:30 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 198 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-17-027164 · doc4.xml · derivative · entry 7 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,152 Underlying: Common Stock · 198 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on April 6, 2016, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 16:30 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,400 | $39.75 | $55,650.00 |
DisclosureSEC source: 0000899243-17-027164 · doc4.xml · nonDerivative · entry 5 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,855 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 16:30 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 601 | $3.40 | $2,043.40 |
DisclosureSEC source: 0000899243-17-027164 · doc4.xml · nonDerivative · entry 4 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 16:30 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 601 | $3.40 | $2,043.40 |
DisclosureSEC source: 0000899243-17-027164 · doc4.xml · nonDerivative · entry 3 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 16:30 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 198 | $3.40 | $673.20 |
DisclosureSEC source: 0000899243-17-027164 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 16:30 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,600 | $39.75 | $63,600.00 |
DisclosureSEC source: 0000899243-17-027164 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,855 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · shares: These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 18:19 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 601 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-17-024433 · doc4.xml · derivative · entry 9 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,882 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 18:19 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 601 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-17-024433 · doc4.xml · derivative · entry 8 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,882 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 18:19 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 198 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-17-024433 · doc4.xml · derivative · entry 7 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,350 Underlying: Common Stock · 198 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on April 6, 2016, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 18:19 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,400 | $32.65 | $45,710.00 |
DisclosureSEC source: 0000899243-17-024433 · doc4.xml · nonDerivative · entry 5 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,455 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 18:19 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 601 | $3.40 | $2,043.40 |
DisclosureSEC source: 0000899243-17-024433 · doc4.xml · nonDerivative · entry 4 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 18:19 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 601 | $3.40 | $2,043.40 |
DisclosureSEC source: 0000899243-17-024433 · doc4.xml · nonDerivative · entry 3 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 18:19 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 198 | $3.40 | $673.20 |
DisclosureSEC source: 0000899243-17-024433 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 18:19 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 1,600 | $32.65 | $52,240.00 |
DisclosureSEC source: 0000899243-17-024433 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,455 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · shares: These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 17:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 601 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-17-023175 · doc4.xml · derivative · entry 9 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,483 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 17:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 601 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000899243-17-023175 · doc4.xml · derivative · entry 8 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,483 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.